Eesti - eesti - Ravimiamet

sopharma ad - desloratadiin - suukaudne lahus - 0,5mg 1ml 120ml 1tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - metoprolool - toimeainet prolongeeritult vabastav tablett - 200mg 30tk; 200mg 56tk; 200mg 20tk; 200mg 50tk; 200mg 14tk; 200mg 98tk; 200mg 28tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - metoprolool - toimeainet prolongeeritult vabastav tablett - 25mg 10tk; 25mg 98tk; 25mg 100tk; 25mg 20tk; 25mg 28tk; 25mg 14tk; 25mg 30tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 8mg 28tk; 8mg 14tk; 8mg 56tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - metoprolool - toimeainet prolongeeritult vabastav tablett - 100mg 60tk; 100mg 20tk; 100mg 10tk; 100mg 30tk; 100mg 100tk; 100mg 14tk; 100mg 56tk; 100mg 28tk; 100mg 98tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - orlistaat - kõvakapsel - 120mg 21tk; 120mg 42tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 4mg 14tk; 4mg 28tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 32mg 56tk; 32mg 14tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 16mg 28tk; 16mg 14tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastilised ained - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.